Abstract
The purpose of this phase I study was to evaluate the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), the recommended dose for phase II study, pharmacokinetics, and antitumor activity of TZT-1,027 (soblidotin) in patients with non-small cell lung cancer (NSCLC) when administered every 3-4 weeks. Eligible patients had the following characteristics: stage III/b or IV NSCLC that was refractory to conventional therapy or for which no standard therapy was available; Eastern Cooperative Oncology Group (ECOG) performance status (PS) <or=2; adequate organ function; and age >or=20 and <75 years. The patients were administered TZT-1,027 in escalating doses from 0.5 to 5.6 mg/m(2). Pharmacokinetic samples were collected during each treatment course. Forty-nine patients were enrolled. Three patients had DLTs, including neutropenia, neutropenia complicated by fever, myalgia, and neuropathic pain. The common toxicities included constipation, anorexia, alopecia, nausea, leukopenia, and neutropenia. One complete response and three partial responses were observed. The pharmacokinetic parameters (AUC and C (max)) of TZT-1,027 tended to increase linearly with dose. DLTs included neutropenia, neutropenia complicated by fever, myalgia, ...Continue Reading
References
Jan 1, 1981·Cancer·A B MillerA Winkler
Oct 1, 1995·Chemical & Pharmaceutical Bulletin·K MiyazakiS Tsukagoshi
Mar 1, 1997·Japanese Journal of Cancer Research : Gann·M KobayashiS Tsukagoshi
Apr 13, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L M KrugM G Kris
May 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F A ShepherdJ Berille
Jun 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F V FossellaL Hammershaimb
Aug 2, 2000·Japanese Journal of Cancer Research : Gann·T NatsumeM Kobayashi
Aug 31, 2000·Japanese Journal of Cancer Research : Gann·M OtaniT Nakayama
Mar 3, 2001·Apoptosis : an International Journal on Programmed Cell Death·J WatanabeM Kobayashi
Apr 28, 2001·Toxicology Letters·T OgawaT Nakayama
Sep 20, 2001·Investigational New Drugs·K MargolinJ H Doroshow
Oct 24, 2002·American Journal of Clinical Oncology·Everardo D SaadJames L Abbruzzese
Apr 16, 2003·Gynecologic Oncology·Mark A HoffmanUNKNOWN Gynecologic Oncology Group Study
Sep 12, 2003·Cancer Science·Tsugitaka NatsumeMotohiro Kobayashi
Mar 23, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P SchöffskiM Satomi
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nasser HannaPaul A Bunn
May 18, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maja J A de JongeJaap Verweij
Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Sep 1, 2005·Investigational New Drugs·Hedy L KindlerEverett E Vokes
Sep 27, 2006·Cancer Science·Junichi WatanabeMotohiro Kobayashi
Citations
Dec 1, 2006·Cancer Chemotherapy and Pharmacology·Kenji TamuraMasahiro Fukuoka
May 4, 2011·Journal of Natural Products·George R PettitSteven Toms
Oct 5, 2010·Nature Reviews. Drug Discovery·Charles Dumontet, Mary Ann Jordan
Mar 14, 2012·Current Opinion in Oncology·Antoine HollebecqueJean-Charles Soria
Feb 10, 2010·Expert Opinion on Investigational Drugs·Si-Meng ChenJian Ding
Jun 24, 2010·Cancer Treatment Reviews·Dietmar W Siemann
Oct 21, 2015·Analytical Cellular Pathology (Amsterdam)·Daniele FanaleViviana Bazan
Feb 24, 2015·Molecular Pharmaceutics·Andreas Maderna, Carolyn A Leverett
May 3, 2016·Marine Drugs·Qi YanYingxia Li
May 30, 2013·Surgical Neurology International·Emory McTyrePrakash Chinnaiyan
Feb 12, 2020·Biomolecules·Edina WangAnabel Sorolla
Jul 5, 2017·Clinical and Experimental Pharmacology & Physiology·Haibo XingDa Li
Oct 7, 2009·Organic Letters·Toshiaki TeruyaKiyotake Suenaga
Jul 3, 2021·Marine Drugs·Gang GaoChunlan Tang